With research funding being slashed across the board, could crowdfunding provide the extra cash needed to develop new treatments? In the next issue we discuss people power with the minds behind Curelauncher, a new clinical research crowdfunding platform in the US.
Go deeper with GlobalData
We also catch up with the clinical trial of the first HIV vaccine, find out how the researchers are manipulating naïve T-cells to study their crucial roles in fighting cancer and HIV, and investigate new breakthroughs in selective tumor targeting.
Moreover, we look at progress in inhalation technologies and what it could mean for respiratory disorders and systemic delivery, and ask how the industry’s quality control standards can be maintained in an outsourced world.
In this issue
People power
Could crowdfunding provide the extra cash needed to develop new treatments? Pharma Technology Focus discusses people power with the minds behind CureLauncher, a clinical research crowdfunding platform in the US.
Click here to read the full article.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHope on the horizon
Last year Canadian scientists claimed they may have discovered the first preventative HIV vaccine that has shown no adverse effects in Phase I trials. We investigate what makes this vaccine different from previous ones that have failed.
Click here to read the full article.
On the right path
US scientists have found a new way of manipulating naïve T-cells to study their roles in fighting cancer and HIV. We ask study author Gregory Tew what these findings hold for future treatments and immunology.
Click here to read the full article.
On target
Antibody-drug conjugates combine the efficacy of cytotoxic drugs and the tumour-specific targeting of antibodies. Pharma Technology Focus explores the potential of this burgeoning treatment.
Click here to read the full article.
Continuous revolution
At the Novartis-MIT center for continuous manufacturing, scientists are using lean engineering principles and sophisticated technology to make a quantum leap forward in the way medicines are manufactured.
Click here to read the full article.
Waiting to inhale
Inhalation technologies have long proven a fertile ground for research. We ask Dr Andy Clark, chief technology officer at Novartis, what the latest developments mean for respiratory disorders and systemic delivery.
Click here to read the full article.
Quality time
As the industry is faced with maintaining quality standards in an increasingly outsourced world, Noven Pharma’s Peter Amanatides explains the challenges of balancing quality with cost.
Click here to read the full article.
Next issue preview
While companies are allowed trade medicines freely within the EU, pricing laws decided by governments have resulted in unequal trade across European borders. We find out what measures are being taken against this and how trade laws are affecting patients and industry.
We also investigate GSK’s pledge to make detailed trial data available and what full disclosure could mean for drug development in the future. Moreover, we explore the Enhanze drug delivery platform which promises to eliminate the need for intravenous delivery of specific drugs, and take a look at temperature controlled packaging and critical stages in the cold chain.
We also chart the rise of Mexico’s pharmaceutical market, and look at new opportunities for biopharma growth in Latin America.
Subscribe for free to get each future issue of Pharma Technology Focus delivered directly to your inbox.
Digital Magazine FAQ
The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.
View the archive of back issues.
